Literature DB >> 21629295

Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets.

Grant R Drummond1, Stavros Selemidis, Kathy K Griendling, Christopher G Sobey.   

Abstract

NADPH oxidases are a family of enzymes that generate reactive oxygen species (ROS). The NOX1 (NADPH oxidase 1) and NOX2 oxidases are the major sources of ROS in the artery wall in conditions such as hypertension, hypercholesterolaemia, diabetes and ageing, and so they are important contributors to the oxidative stress, endothelial dysfunction and vascular inflammation that underlies arterial remodelling and atherogenesis. In this Review, we advance the concept that compared to the use of conventional antioxidants, inhibiting NOX1 and NOX2 oxidases is a superior approach for combating oxidative stress. We briefly describe some common and emerging putative NADPH oxidase inhibitors. In addition, we highlight the crucial role of the NADPH oxidase regulatory subunit, p47phox, in the activity of vascular NOX1 and NOX2 oxidases, and suggest how a better understanding of its specific molecular interactions may enable the development of novel isoform-selective drugs to prevent or treat cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21629295      PMCID: PMC3361719          DOI: 10.1038/nrd3403

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  225 in total

1.  Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice.

Authors:  Sulochana S Bhandarkar; Marisa Jaconi; Levi E Fried; Michael Y Bonner; Benjamin Lefkove; Baskaran Govindarajan; Betsy N Perry; Ravi Parhar; Jamie Mackelfresh; Allie Sohn; Michael Stouffs; Ulla Knaus; George Yancopoulos; Yvonne Reiss; Andrew V Benest; Hellmut G Augustin; Jack L Arbiser
Journal:  J Clin Invest       Date:  2009-07-13       Impact factor: 14.808

2.  Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells.

Authors:  Alicia N Lyle; Nita N Deshpande; Yoshihiro Taniyama; Bonnie Seidel-Rogol; Lily Pounkova; Pingfeng Du; Christopher Papaharalambus; Bernard Lassègue; Kathy K Griendling
Journal:  Circ Res       Date:  2009-07-02       Impact factor: 17.367

Review 3.  p47phox, the phagocyte NADPH oxidase/NOX2 organizer: structure, phosphorylation and implication in diseases.

Authors:  Jame El-Benna; Pham My-Chan Dang; Marie Anne Gougerot-Pocidalo; Jean Claude Marie; Francoise Braut-Boucher
Journal:  Exp Mol Med       Date:  2009-04-30       Impact factor: 8.718

4.  NADPH oxidase is the primary source of superoxide induced by NMDA receptor activation.

Authors:  Angela M Brennan; Sang Won Suh; Seok Joon Won; Purnima Narasimhan; Tiina M Kauppinen; Hokyou Lee; Ylva Edling; Pak H Chan; Raymond A Swanson
Journal:  Nat Neurosci       Date:  2009-06-07       Impact factor: 24.884

5.  Nox4 mediates the expression of plasminogen activator inhibitor-1 via p38 MAPK pathway in cultured human endothelial cells.

Authors:  Amandine Jaulmes; Patricia Sansilvestri-Morel; Gaëlle Rolland-Valognes; Fabienne Bernhardt; Roger Gaertner; Brian P Lockhart; Alex Cordi; Michel Wierzbicki; Alain Rupin; Tony J Verbeuren
Journal:  Thromb Res       Date:  2009-06-21       Impact factor: 3.944

Review 6.  Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease.

Authors:  Carol Wadham; Arduino A Mangoni
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-03       Impact factor: 4.481

7.  NADPH oxidase isoform selective regulation of endothelial cell proliferation and survival.

Authors:  Hitesh Peshavariya; Gregory J Dusting; Fan Jiang; Lesley R Halmos; Christopher G Sobey; Grant R Drummond; Stavros Selemidis
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-04-01       Impact factor: 3.000

8.  Inhibition of NADPH oxidase is neuroprotective after ischemia-reperfusion.

Authors:  Hai Chen; Yun Seon Song; Pak H Chan
Journal:  J Cereb Blood Flow Metab       Date:  2009-05-06       Impact factor: 6.200

9.  Importance of NOX1 for angiotensin II-induced cerebrovascular superoxide production and cortical infarct volume following ischemic stroke.

Authors:  Katherine A Jackman; Alyson A Miller; Grant R Drummond; Christopher G Sobey
Journal:  Brain Res       Date:  2009-06-25       Impact factor: 3.252

10.  NADPH oxidase 1 deficiency alters caveolin phosphorylation and angiotensin II-receptor localization in vascular smooth muscle.

Authors:  Olivier Basset; Christine Deffert; Michelangelo Foti; Karen Bedard; Vincent Jaquet; Eric Ogier-Denis; Karl-Heinz Krause
Journal:  Antioxid Redox Signal       Date:  2009-10       Impact factor: 8.401

View more
  334 in total

Review 1.  The Nox family of NADPH oxidases: friend or foe of the vascular system?

Authors:  Ina Takac; Katrin Schröder; Ralf P Brandes
Journal:  Curr Hypertens Rep       Date:  2012-02       Impact factor: 5.369

Review 2.  Targeting NADPH oxidases in vascular pharmacology.

Authors:  Agata Schramm; Paweł Matusik; Grzegorz Osmenda; Tomasz J Guzik
Journal:  Vascul Pharmacol       Date:  2012-03-03       Impact factor: 5.773

3.  Off-target thiol alkylation by the NADPH oxidase inhibitor 3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo[4,5-d]pyrimidine (VAS2870).

Authors:  Qi-An Sun; Douglas T Hess; Benlian Wang; Masaru Miyagi; Jonathan S Stamler
Journal:  Free Radic Biol Med       Date:  2012-03-08       Impact factor: 7.376

Review 4.  NADPH oxidases: novel therapeutic targets for neurodegenerative diseases.

Authors:  Hui-Ming Gao; Hui Zhou; Jau-Shyong Hong
Journal:  Trends Pharmacol Sci       Date:  2012-04-11       Impact factor: 14.819

5.  NOX2-dependent ROS is required for HDAC5 nuclear efflux and contributes to HDAC4 nuclear efflux during intense repetitive activity of fast skeletal muscle fibers.

Authors:  Yewei Liu; Erick O Hernández-Ochoa; William R Randall; Martin F Schneider
Journal:  Am J Physiol Cell Physiol       Date:  2012-05-30       Impact factor: 4.249

6.  Hydrogen sulfide treatment reduces blood pressure and oxidative stress in angiotensin II-induced hypertensive mice.

Authors:  Mohammad R Al-Magableh; Barbara K Kemp-Harper; Joanne L Hart
Journal:  Hypertens Res       Date:  2014-08-07       Impact factor: 3.872

7.  The transcription factor CREB enhances interleukin-17A production and inflammation in a mouse model of atherosclerosis.

Authors:  Sivareddy Kotla; Nikhlesh K Singh; Mark R Heckle; Gabor J Tigyi; Gadiparthi N Rao
Journal:  Sci Signal       Date:  2013-09-17       Impact factor: 8.192

Review 8.  Role of NADPH oxidases in liver fibrosis.

Authors:  Yong-Han Paik; Jonghwa Kim; Tomonori Aoyama; Samuele De Minicis; Ramon Bataller; David A Brenner
Journal:  Antioxid Redox Signal       Date:  2014-01-24       Impact factor: 8.401

Review 9.  Reactive oxygen species: key regulators in vascular health and diseases.

Authors:  Qishan Chen; Qiwen Wang; Jianhua Zhu; Qingzhong Xiao; Li Zhang
Journal:  Br J Pharmacol       Date:  2017-07-11       Impact factor: 8.739

10.  PKCε mediates resistin-induced NADPH oxidase activation and inflammation leading to smooth muscle cell dysfunction and intimal hyperplasia.

Authors:  Gayatri Raghuraman; Mary C Zuniga; Hai Yuan; Wei Zhou
Journal:  Atherosclerosis       Date:  2016-08-20       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.